Medivir AB (OSTO:MVIR) Cyclically Adjusted FCF per Share: kr-4.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MVIR Medivir AB OSTO:MVIR
50 GF Score
Price kr1.80
GF Value kr1.11
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medivir AB Cyclically Adjusted FCF per Share?

Medivir AB OSTO:MVIR -1.10% 50 Cyclically Adjusted FCF per Share is kr-4.74 as of Mar. 2026. GuruFocus rates OSTO:MVIR with a GF Score™ of 50/100 and a GF Value™ of kr1.11 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Medivir AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.027. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-4.74 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -99.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -57.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Medivir AB was -2.30% per year. The lowest was -99.70% per year. And the median was -14.90% per year.

As of today (2026-08-04), Medivir AB's current stock price is kr1.80. Medivir AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-4.74. Medivir AB's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Medivir AB was 1404.28. The lowest was 26.87. And the median was 53.56.


Medivir AB  (OSTO:MVIR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Medivir AB was 1404.28. The lowest was 26.87. And the median was 53.56.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Medivir AB Cyclically Adjusted FCF per Share Related Terms


Medivir AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Medivir AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Cyclically Adjusted FCF per Share Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -0.61 -0.85 -3.78 -4.86

Medivir AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.42 -4.64 -4.87 -4.86 -4.74

OSTO:MVIR vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:MVIR
50GF Score
Medivir AB OSTO:MVIR
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medivir AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.027/133.5600*133.5600
=-0.027

Current CPI (Mar. 2026) = 133.5600.

Medivir AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.041 101.019 -1.376
201609 -1.039 101.138 -1.372
201612 -4.153 102.022 -5.437
201703 -3.762 102.022 -4.925
201706 -2.417 102.752 -3.142
201709 -2.132 103.279 -2.757
201712 -2.976 103.793 -3.830
201803 -2.613 103.962 -3.357
201806 -2.357 104.875 -3.002
201809 -2.249 105.679 -2.842
201812 -1.957 105.912 -2.468
201903 -1.565 105.886 -1.974
201906 -0.983 106.742 -1.230
201909 -0.889 107.214 -1.107
201912 -0.662 107.766 -0.820
202003 -0.560 106.563 -0.702
202006 -0.786 107.498 -0.977
202009 -0.577 107.635 -0.716
202012 -0.026 108.296 -0.032
202103 -0.028 108.360 -0.035
202106 -0.322 108.928 -0.395
202109 -0.294 110.338 -0.356
202112 -0.080 112.486 -0.095
202203 -0.586 114.825 -0.682
202206 -0.259 118.384 -0.292
202209 -0.290 122.296 -0.317
202212 -0.363 126.365 -0.384
202303 -0.289 127.042 -0.304
202306 -0.323 129.407 -0.333
202309 -0.370 130.224 -0.379
202312 -0.063 131.912 -0.064
202403 -0.310 132.205 -0.313
202406 -0.231 132.716 -0.232
202409 -0.291 132.304 -0.294
202412 -0.257 132.987 -0.258
202503 -0.234 132.825 -0.235
202506 -0.229 133.699 -0.229
202509 -0.123 133.480 -0.123
202512 -0.028 133.390 -0.028
202603 -0.027 133.560 -0.027

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-4.74 mean?
Medivir AB (OSTO:MVIR) has a Cyclically Adjusted FCF per Share of kr-4.74 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medivir AB and its competitors.
Is Medivir AB's Cyclically Adjusted FCF per Share too high?
Medivir AB's current Cyclically Adjusted FCF per Share is kr-4.74. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Medivir AB's Cyclically Adjusted FCF per Share of kr-4.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medivir AB and its competitors. Medivir AB's current Cyclically Adjusted FCF per Share is kr-4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-4.74. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current Cyclically Adjusted FCF per Share is kr-4.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (OSTO:MVIR) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for OSTO:MVIR:

  • Cyclically Adjusted FCF per Share: kr-4.74
  • GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Other Exchanges MVIRs:UK0GP7:UKMVR0:Germany
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score

Get the complete analysis for OSTO:MVIR

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.80
Price
kr1.11
GF Value